Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells

Ping Liang; Hongming Shi; Weiguo Zhu; Qunfeng Gui; Ya Xu; Jianfeng Meng; Xiaoyuan Guo; Zhuang Gong; Huaqun Chen

doi:10.18632/oncotarget.13503

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells

Ping Liang, Hongming Shi, Weiguo Zhu, Qunfeng Gui, Ya Xu, Jianfeng Meng, Xiaoyuan Guo, Zhuang Gong and Huaqun Chen _

PDF | HTML | How to cite

Oncotarget. 2017; 8:7533-7539. https://doi.org/10.18632/oncotarget.13503

Metrics: PDF 2457 views | HTML 2951 views | ?

Abstract

Ping Liang1, Hongming Shi1, Weiguo Zhu1, Qunfeng Gui1, Ya Xu1, Jianfeng Meng1, Xiaoyuan Guo2, Zhuang Gong3, Huaqun Chen1

1Department of Neurology, Yancheng Hospital Affiliated to Southeast University, Yancheng, 224001, China

2Department of Neurology, Zhongda Hospital Affiliated to Southeast University, Nanjing, 210009, China

3Department of Nephrology, The First People’s Hospital of Yancheng Affiliated to Nantong University, Yancheng, 224001, China

Correspondence to:

Huaqun Chen, email: [email protected]

Keywords: silver nanoparticles (AgNPs), glioma cells, temozolomide (TMZ), chemotherapy

Received: August 20, 2016 Accepted: November 07, 2016 Published: November 22, 2016

ABSTRACT

Glioblastoma multiforme (GBM) continues to be associated with a dismal prognosis despite aggressive treatment. Significant efforts are being made to develop new nanotechnology-based therapeutic and diagnostic agents. Nanoparticles can act directly on cancer cells or as drug carriers to enhance the cancer therapeutic effect. In this study, we investigated the effect of silver nanoparticles (AgNPs) on human glioma U251 cells and its role in the combinational use with Temozolomide (TMZ), an imidazotetrazine derivative of the alkylating agent dacarbazine, against glioma cells. AgNPs were synthesized in the sodium citrate system and the mean size were 26 nm in diameter. The AgNP particles showed dose-dependent cytotoxicity on U251 cells. They also showed the ability to enhance the drug-sensitivity of TMZ on U251 cells. Our results revealed that AgNPs could have a potential application in enhancing chemotherapy for glioma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13503

Publication Alerts

Research Papers:

Silver nanoparticles enhance the sensitivity of temozolomide on human glioma cells

Abstract